GLYBURIDE (MICRONIZED)
LOE ApproachingNDAORALTABLET
Approved
Apr 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Glyburide (Micronized) is an oral small-molecule sulfonylurea approved in 1992 for type 2 diabetes management. It lowers blood glucose by stimulating insulin secretion from pancreatic beta cells. The micronized formulation enhances bioavailability compared to conventional glyburide.
LOE Approaching
As an approaching LOE product with moderate competitive pressure (30%), brand teams face defensive positioning and likely resource constraints.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on glyburide (micronized) offers limited career growth due to its LOE-approaching status and minimal linked job postings. Roles focus on defensive maintenance, market share retention, and managed decline rather than growth-oriented activities.
Brand ManagerField Sales Representative
Worked on GLYBURIDE (MICRONIZED) at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.